Create a free account to see ACCE Scores
Sign up for free to unlock scores, score breakdowns, and stock analysis.
BCRX
↓ PDF (Pro)BioCryst Pharmaceuticals Inc. Common Stock
HealthcareDrug Manufacturers - Specialty & GenericUnited StatesNASDAQ
$8.87
-1.83%today
MKT CAP
$2.3B
-6.2% · 1Y
Earnings History
+100.0%
+47.1%
+125.3%
+197.6%
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Analyst Targets
Current price
$8.87
Low
$14.00
Analyst Mean
$21.40
High
$32.00
10 analystsStrong Buy
Full Financials
Trailing P/E-
Forward P/E11.7x
EV/EBITDA-
Price/Sales-
Dividend Yield-
Revenue Growth YoY-
Earnings Growth YoY-
Revenue Growth QoQ+155.1%
5y Revenue CAGR+47.8%
5y Earnings CAGR-
Gross Margin-
Operating Margin-
Net Margin-
ROE-
Debt / Equity-
Free Cash Flow-
Insider Ownership1.1%
Institutional Ownership91.4%
Short % of Float15.28%
Days to Cover5.7d
1 Week+2.6%
1 Month-
3 Months-
6 Months-
YTD-
1 Year-
3 Years-
5 Years-
vs 50-day SMA-
vs 200-day SMA-
vs 52w High-
vs 52w Low-
Insider Transactions
| Filer | Role | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| MENON SANDEEP | Officer | Stock | 205,150 | $0.00 | $0.00M | 2026-04-06 |
| HEGGIE THERESA | Director | Sale | 49,933 | $10.11 | $0.50M | 2026-03-20 |
| HEGGIE THERESA | Director | Conversion | 49,933 | $6.30 | $0.31M | 2026-03-20 |
| BARNES ALANE P | Officer | Sale | 150,000 | $9.15 | $1.37M | 2026-03-16 |
| BARNES ALANE P | Officer | Conversion | 150,000 | $5.51 | $0.83M | 2026-03-16 |
Top Holders
| Holder | Type | % Held | Value | Δ Shares | As of |
|---|---|---|---|---|---|
| Vanguard Group Inc | institution | 8.77% | $0.20B | +2.21% | 2025-12-31 |
| Blackrock Inc. | institution | 8.32% | $0.19B | -0.51% | 2025-12-31 |
| RA Capital Management, L.P. | institution | 6.23% | $0.14B | +100.00% | 2025-12-31 |
| Deerfield Management Company, L.P | institution | 5.64% | $0.13B | +17.85% | 2025-12-31 |
| State Street Corporation | institution | 4.36% | $0.10B | +12.91% | 2025-12-31 |
| Kynam Capital Management, LP | institution | 3.69% | $0.08B | -0.25% | 2025-12-31 |
| Janus Henderson Group PLC | institution | 2.91% | $0.07B | +7807.21% | 2025-12-31 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | fund | 2.74% | $0.06B | +9.36% | 2026-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | fund | 2.60% | $0.06B | -0.20% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | fund | 2.17% | $0.05B | -3.78% | 2026-03-31 |
| UBS Group AG | institution | 2.07% | $0.05B | -11.79% | 2025-12-31 |
| Geode Capital Management, LLC | institution | 1.99% | $0.05B | +0.03% | 2025-12-31 |
| Aberdeen Group plc | institution | 1.98% | $0.05B | +451.74% | 2026-03-31 |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Equity Fund | fund | 1.01% | $0.02B | +32.78% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | fund | 0.94% | $0.02B | -4.07% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | fund | 0.89% | $0.02B | +0.81% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | fund | 0.89% | $0.02B | +10.21% | 2026-01-31 |
| iShares Trust-iShares Biotechnology ETF | fund | 0.68% | $0.02B | +0.98% | 2026-03-31 |
| iShares Trust-iShares Russell 2000 Growth ETF | fund | 0.65% | $0.01B | -5.86% | 2026-03-31 |
| Vanguard Explorer Fund | fund | 0.61% | $0.01B | +0.00% | 2026-01-31 |
| Ticker | Cap | Score | P/E | Fwd P/E | EV/EBITDA | ROE | Gross | D/E | Div |
|---|---|---|---|---|---|---|---|---|---|
| HCM | $2.3B | 67 | 5.0 | 25.5 | - | - | - | - | 0.00% |
| PAHC | $2.3B | 51 | 19.1 | 12.7 | - | - | - | - | 82.00% |
| BHC | $2.1B | 100 | - | 1.4 | - | - | - | - | 0.00% |
| PBH | $2.5B | 80 | 14.3 | 11.3 | - | - | - | - | 0.00% |
| ANIP | $1.9B | 73 | 25.3 | 7.9 | - | - | - | - | 0.00% |
| AMLX | $1.8B | - | - | - | - | - | - | - | 0.00% |
Peers selected by sector + industry + nearest market cap. Best in column highlighted green, worst red.
Unlock Full Financials
Growth metrics, valuation multiples, and profitability ratios on Starter+.
Recent Alerts
No alerts yet for BCRX.
Want deep analysis?
This stock isn't in the ACCE researched universe. Browse 300+ stocks with full thesis, scores, and financial models.
Browse ACCE Indices →Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.